Evolution of the Average Target: Lexicon Pharmaceuticals, Inc.

Evolution of the Target Price: Lexicon Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Lexicon Pharmaceuticals, Inc.

4ab3.oxgrbNLSjV_wTvBVSGN6Ujiy3ZR_EMMzn71hZPcP8a4.8FNKIaTqvzuxJbwiBlVJMVyEm_sFXfYC6dwIVdpVsJbLSGMVlo3fab8WxA~fa82062a3e9562e261e0afc53a5321ef
09-28 Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating MT
09-28 Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target MT
11-07 Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025 CI
05/03/25 Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 MT
22/11/24 HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating MT
17/06/24 HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target MT
30/04/24 Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target MT
31/05/23 Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating MT
07/03/23 Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target MT
12/08/22 Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target MT
01/07/22 Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating MT
11/10/21 Lexicon Pharmaceuticals : Wedbush Suspended Coverage on Lexicon Pharmaceuticals MT
30/08/21 Lexicon Pharmaceuticals : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating MT
11/05/21 Lexicon Pharmaceuticals : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept MT
29/01/21 Lexicon Pharmaceuticals : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7 MT
29/01/21 Lexicon Pharmaceuticals : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2 MT
08/12/20 Lexicon Pharmaceuticals : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10 MT
18/11/20 Lexicon Pharmaceuticals : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold MT
03/11/20 Lexicon Pharmaceuticals : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+149.82%
+11.79%
+27.75%
+21.67%
+24.6%
+11.82%
+21.07%
+46.63%
+6.77%
+20.91%
Average +34.28%
Weighted average by Cap. +20.99%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.820USD
Average target price
4.547USD
Spread / Average Target
+149.82%
High Price Target
8.000USD
Spread / Highest target
+339.56%
Low Price Target
2.000USD
Spread / Lowest Target
+9.89%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. LXRX Stock
  4. Consensus Lexicon Pharmaceuticals, Inc.